-
Eisai and Biogen self-injected Alzheimer drug wins US approval
31 Aug 2025 21:37 GMT
… , the FDA has required Eisai to update prescribing information for … prevent serious or fatal events,” Eisai said in a statement, … , Biogen reported in July.
Eisai and Biogen are also working … systemic reactions.
Leqembi’s primary competitor is Eli Lilly & …
-
Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosing
30 Aug 2025 03:48 GMT
… on the initiation dose, Eisai said in its approval announcement … s approved Alzheimer’s disease competitor Kisunla only targets plaque … uses weight-based dosing.
“Eisai’s pricing reflects the balance … maintenance dose in hand, Eisai will waste no time pursuing …
-
Eisai execs flag Leqembi 'expansion phase' on the horizon as Alzheimer's med grows slowly
11 Feb 2025 18:17 GMT
… accurate blood-based diagnostics. Eisai expects that regulators will allow … amyloid plaque, Haruna explained.
Eisai has highlighted Leqembi’s … lose unit share from the competitors,” Haruna said of the … , Haruna said.
Overall, Eisai generated 601.2 billion yen …
-
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
24 Jan 2025 12:04 GMT
… (TKI) discovered by Eisai, in combination with chemotherapy … of cancers.
About Eisai
Eisai’s Corporate Concept is … Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai … and patents attained by competitors; challenges inherent in …
-
Fosravuconazole by Eisai for Tinea Pedis (Athlete Foot): Likelihood of Approval
26 Dec 2024 22:03 GMT
… of Chagas disease.
Eisai overview
Eisai is a pharmaceutical company … include neurology and oncology. Eisai’s major products include … and peripheral neuropathy. Eisai has production plants in … -proof advantage over your competitors.
Be better informed
GlobalData …
-
Insomnia Drugs Business Research Report 2023-2030 Featuring Astellas Pharma, Eisai, Flynn Pharma, Johnson & Johnson, Meda, Merck, Pfizer, Sanofi, and Takeda - ResearchAndMarkets.com
03 Sep 2024 18:32 GMT
… such as Astellas Pharma, Inc., Eisai Co., Ltd., Flynn Pharma Limited …
Insomnia Drugs - Global Key Competitors Percentage Market Share in 2024 … 31 Featured)
Astellas Pharma, Inc.
Eisai Co., Ltd.
Flynn Pharma Limited …
-
Kidney Cancer Drugs Global Strategic Business Report 2023-2030 With Focus on Key Players Including Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, and Pfizer - ResearchAndMarkets.com
22 Aug 2024 05:11 GMT
… AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and more.
Complimentary … Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 … AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
Novartis …
-
Fierce Pharma Asia—BMS, Eisai's ADC divorce; Takeda's US layoffs; House Speaker's BIOSECURE pledge
12 Jul 2024 15:12 GMT
… time, Bristol Myers Squibb returned Eisai's FRα-targeted … 202), which is a potential competitor to AbbVie’s newly bought … exclusive rights in other countries. Eisai now aims to “accelerate the … with inflammatory disease portfolio from Eisai's EA Pharm
…
-
Game on: Lilly's Alzheimer's drug Kisunla, a challenger to Biogen and Eisai's Leqembi, gains full FDA nod
02 Jul 2024 20:35 GMT
… anti-amyloid therapy—and a competitor to Eisai and Biogen’s Leqembi … for multiple players. Besides, the competitor launch should accelerate the uptake … moment, given that Biogen and Eisai's Leqembi—and Aduhelm …
-
Perampanel API Market Growing Up on Changing Dynamics: Teva Pharmaceutical, Eisai, Qingfeng Pharmaceutical
26 Jun 2024 08:18 GMT
… upcoming challenges and about the competitors.
Key Players in This Report … Pharmaceutical (Israel), Intas Pharma (India), Eisai (Japan), Jiangsu Kangyuan Pharmaceutical (China …
About
© 1995-2025